1 Risk factors for long covid in previously hospitalised children using the

2 ISARIC Global follow-up protocol: A prospective cohort study

- 3 Ismail M Osmanov MD PhD^{1,2*}, Ekaterina Spiridonova BSc^{3*}, Polina Bobkova BSc^{3*}, Aysylu
- Gamirova BSc^{3*}, Anastasia Shikhaleva BSc^{3*}, Margarita Andreeva BSc^{3*}, Oleg Blyuss
 PhD^{3,4,*}, Yasmin El-Taravi BSc³, Audrev DunnGalvin PhD^{3,5}, Pasquale Comberiati MD⁶.
- 5 PhD^{3,4,*}, Yasmin El-Taravi BSc³, Audrey DunnGalvin PhD^{3,5}, Pasquale Comberiati MD⁶,
 6 Diego G Peroni MD PhD⁶, Christian Apfelbacher PhD⁷, Jon Genuneit MD PhD⁸, Lvudmila
- 7 Mazankova MD PhD⁹, Alexandra Miroshina MD PhD¹, Evgeniya Chistyakova MD PhD¹⁰
- 8 Elmira Samitova MD PhD^{1,9}, Svetlana Borzakova MD PhD^{2,11}, Elena Bondarenko³, Anatoliy A
- 9 Korsunskiy MD PhD³, Irina Konova MD¹, Sarah Wulf Hanson PhD¹², Gail Carson MD PhD¹³,
- 10 Louise Sigfrid MD PhD¹³, Janet T Scott MD PhD¹⁴, Matthew Greenhawt MD MBA¹⁵,
- 11 Elizabeth A Whittaker MD PhD¹⁶, Elena Garralda MD PhD¹⁷, Olivia Swann MD PhD^{18,19},
- 12 Danilo Buonsenso MD^{20,21,22}, Dasha E Nicholls MD PhD¹⁷, Frances Simpson MSc²³, Christina
- 13 Jones MD PhD²⁴, Malcolm G Semple MD PhD^{25,26}, John O Warner MD FMedSci²⁷, Theo Vos
- 14 PhD¹², Piero Olliaro MD PhD¹³, Daniel Munblit MD PhD^{3,27,28*} and Sechenov StopCOVID
- 15 Research Team
- 16 1. ZA Bashlyaeva Children's Municipal Clinical Hospital, Moscow, Russia
- 17 2. Pirogov Russian National Research Medical University, Moscow, Russia
- 18 3. Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health,
 19 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
- 20 4. School of Physics, Astronomy and Mathematics, University of Hertfordshire, College Lane,
 21 Hatfield, United Kingdom
- 22 5. School of Applied Psychology, University College Cork, Cork City, Ireland
- 23 6. Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa,
 24 Italy
- 25 7. Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke
 26 University Magdeburg, Magdeburg, Germany
- 8. Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig,
 Germany
- 29 9. Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of
 30 the Russian Federation, Moscow, Russia
- 31 10. Department of Paediatrics and Paediatric Rheumatology, Institute of Child's Health, Sechenov
 32 First Moscow State Medical University (Sechenov University), Moscow, Russia
- Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare
 Department, Moscow, Russia
- 35 12. Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA
- 36 13. ISARIC Global Support Centre, Nuffield Department of Medicine, University of Oxford, Oxford,
 37 UK
- 38 14. MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
- 15. Department of Pediatrics, Section of Allergy/Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, United States
- 42 16. Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK
- 43 17. Division of Psychiatry, Imperial College London, London, UK
- 18. Department of Child Life and Health, University of Edinburgh, Edinburgh, UK
 - 19. Royal Hospital for Children, Paediatric Infectious Diseases, Glasgow, UK

- 45
 46
 47
 48
 49
 49
 40
 40
 41
 41
 42
 43
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 44
 <
- 21. Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie,
 49 Università Cattolica del Sacro Cuore, Rome, Italy

22. Center for Global Health Research and Studies, Università Cattolica del Sacro Cuore, Roma, Italia

- 51 23. Coventry University, Coventry, UK
- 24. School of Psychology, Faculty of Health & Medical Sciences, University of Surrey, Guildford, UK
- 52 25. Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection,
 53 Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool,
 54 Liverpool, UK
- 55 26. Department of Respiratory Medicine, Alder Hey Children's Hospital, Liverpool, UK
- 56 27. Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of
 57 Medicine, Imperial College London, London, United Kingdom
- 58 28. Research and Clinical Center for Neuropsychiatry, Moscow, Russia

59

60 *Authors contributed equally to the paper.

61

62 Corresponding author:

- 63 Daniel Munblit, MD, PhD. Department of Paediatrics and Paediatric Infectious Diseases, Institute of
- 64 Child's Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow,
- 65 Russia and Inflammation, Repair and Development Section, National Heart and Lung Institute,
- 66 Faculty of Medicine, Imperial College London, London, United Kingdom
- 67 Email: <u>daniel.munblito8@imperial.ac.uk</u>

69 Sechenov StopCOVID Research Team (Group authors)

70 Elina Abdeeva¹, Nikol Alekseeva¹, Anastasiia Bairashevskaia¹, Dina Baimukhambetova¹, 71 Lusine Baziyants¹, Anna Berbenyuk¹, Tatiana Bezbabicheva¹, Julia Chayka¹, Salima 72 Deunezhewa¹, Yulia Filippova¹, Svetlana Gadetskaya², Anastasia Gorina¹, Cyrill Gorlenko¹, 73 Yulia V Ivanova², Margarita Kalinina¹, Bogdan Kirillov¹, Herman Kiseljow¹, Natalya Kogut¹, 74 Mariia Korgunova¹, Anastasia Kotelnikova¹, Alexandra Krupina¹, Anna Kuznetsova¹, 75 Anastasia Kuznetsova¹, Veronika Laukhina¹, Baina Lavginova¹, Elza Lidjieva¹, Nadezhda 76 Markina¹, Daria Nikolaeva¹, Georgiy Novoselov¹, Polina Petrova¹, Erika Porubayeva¹, Kristina 77 Presnyakova¹, Anna Pushkareva¹, Mikhail Rumyantsev¹, Ilona Sarukhanyan¹, Jamilya 78 Shatrova¹, Nataliya Shishkina¹, Anastasia Shvedova¹, Valeria Ustyan¹, Maria Varaksina¹, 79 Ekaterina Varlamova¹, Margarita Yegiyan¹, Elena Zuykova¹

- 80 81
- 82
- 83
- Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia 1.
- Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child's Health, 2. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
- 84 85
- 86 87

The names of the authors are in alphabetic order

- 88 89
- 90

91 Word count: 3,294

94 ABSTRACT

Background The long-term sequelae of coronavirus disease 2019 (Covid-19) in children
remain poorly characterised. This study aimed to assess long-term outcomes in children
previously hospitalised with Covid-19 and associated risk factors.

Methods This is a prospective cohort study of children (≤18 years old) admitted with
confirmed Covid-19 to Z.A. Bashlyaeva Children's Municipal Clinical Hospital in Moscow,
Russia. Children admitted to the hospital during the first wave of the pandemic, between
April 2, 2020 and August 26, 2020, were included. Telephone interview using the
International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) CovidHealth and Wellbeing paediatric follow up survey. Persistent symptoms (>5 months) were
further categorised by system(s) involved.

105

106 Findings Overall, 518 of 853 (61%) of eligible children were available for the follow-up 107 assessment and included in the study. Median age was 10.4 years (IQR, 3-15.2) and 270 108 (52.1%) were girls; median follow-up since hospital discharge was 256 (223-271) days. At the 109 time of the follow-up interview 126 (24.3%) participants reported persistent symptoms 110 among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%) and sensory problems (29, 111 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: age "6-11 years" (odds ratio 2.74 112 (95% confidence interval 1.37 to 5.75) and "12-18 years" (2.68, 1.41 to 5.4), and a history of 113 114 allergic diseases (1.67, 1.04 to 2.67).

115

Interpretation A quarter of children experienced persistent symptoms months after hospitalization with acute covid-19 infection, with almost one in ten experiencing multisystem involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up. Our findings highlight the need for replication and further investigation of potential mechanisms as well as clinical support to improve long term outcomes in children.

- 122
- 123 **Funding** None.

Research in context

Evidence before this study

Evidence suggests that Covid-19 may result in short- and long-term consequences to health. Studies in children and adolescents are limited and available evidence is scarce. We searched Embase for publications from inception to April, 25, 2021, using the following phrases or combinations of phrases "post-covid condition" or "post-covid syndrome" or "covid sequalae" or "post-acute covid" or "long covid" or "long hauler" with "pediatric*" or "paediatric*" or "child*" or "infant*" or "newborn*" or "toddler*" or "neonate*" or "neonatal" or "adolescent*" or "teen*". We found small case series and small cohort studies looking at Covid-19 consequences in children. No large cohort studies of previously hospitalised children, assessing symptom duration, categorisation or attempting multivariable analyses to identify independent risk factors for long Covid development were identified.

Added value of this study

To our knowledge, this is the largest cohort study with the longest follow-up since hospital discharge of previously hospitalised children. We found that even months after discharge from the hospital, approximately a quarter of children experience persistent symptoms with one in ten having multi-system involvement. Older age and allergic diseases are associated with Covid-19 consequences. Parents of some children report emotional and behavioural changes in their children after Covid-19.

Implications of all the available evidence

Our findings highlight the need for continued global research of Covid-19 consequences in the paediatric population. Older children admitted to the hospital should be carefully monitored upon discharge. Large, controlled studies aiming to identify risk groups and potential intervention strategies are required to fill knowledge gaps.

125 INTRODUCTION

The Covid-19 pandemic has, at the time of writing, affected over 135 million people 126 127 worldwide ¹, with adverse impacts on physical and psychological health and over 3 million 128 deaths. While our knowledge of the acute phase of the disease has increased over time, 129 evidence on the longer-term health consequences of covid-19 is still limited. Emerging data 130 suggest that a substantial proportion of people experience ongoing symptoms including 131 fatigue and muscle weakness, breathlessness, and neurological problems more than 6 months after the acute phase 2.3. This phenomenon is commonly referred to as 'long Covid', a 132 133 term defined by patient groups, and also known as post-Covid syndrome, the post-Covid-19 134 condition 4 or 'Covid long-haulers ^{5,6}. Recent population data from the UK reported that the 135 highest prevalence of long Covid after 12 weeks was among those aged 25 to 34 years (18.2%) 136 and lowest in the 2 to 11 years age bracket (7.4%)7.

137

138 Children and adolescents are at lower risk of severe Covid-19 illness compared to adults ⁸ 139 and may present with a wide range of clinical features and symptoms at the time of hospital 140 admission 9-11. Data suggest that among children hospitalised with Covid-19, up to a third of 141 patients require intensive care (ICU) ¹² with premature infants at higher risk¹⁰. Among 142 children admitted to ICU, some experience single or multi-organ failure and many require 143 respiratory support. A small number of patients develop a severe condition called 144 multisystem inflammatory syndrome in children (MIS-C), which usually appears a few weeks 145 after the acute infection ¹³. Evidence on post-acute covid condition and long term outcomes 146 in children is still limited to small studies with more than half having at least one persisting 147 symptom 4 months after covid-19 infection ¹⁴. However, a recent publication from Australia 148 suggested that only 8% of children aged 0-19 years (median 3 years) had ongoing symptoms 149 3-6 months after predominantly mild covid-19 infection. The limitation of the study as 150 acknowledged by the authors was the low age range. This mandates the inclusion larger 151 numbers particularly of older children in future studies ¹⁵.

152

153 There is a need to assess the long-term consequences of Covid-19 in paediatric populations 154 ¹⁶, to inform clinicians, researchers and public health experts and address the impacts of this 155 condition on the quality of life (OoL) of those affected and their families and to inform 156 discussions on vaccination of children. This cohort study aimed to investigate the incidence 157 of and risk factors for long-term Covid-19 outcomes in children post-hospital discharge. We 158 used the standardised follow-up data collection protocol developed by the International 159 Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Global Paediatric 160 Covid-19 follow up working group ¹⁷.

162 METHODS

163 Study design, setting and participants

164 This is a prospective cohort study of children (≤ 18 years old) admitted with suspected or 165 confirmed Covid-19 to Z.A. Bashlyaeva Children's Municipal Clinical Hospital in Moscow, 166 Russia. This large tertiary university hospital can accommodate up to 980 children at a time 167 and served as the primary Covid-19 hospital for children residing in Moscow city. Children 168 admitted to the hospital during the first wave of the pandemic, between April 2, 2020 and 169 August 26, 2020, with reverse transcriptase polymerase chain reaction (RT-PCR) confirmed 170 SARS-CoV-2 infection were included. The parents of these children were contacted between 171 January 31, 2021 and February 27, 2021 to complete a follow up survey for this study.

172

The acute-phase data were extracted from electronic medical records (EMR) and the Local Health Information System (HIS) at the host institution. The acute-phase dataset included demographics, symptoms, co-morbidities, chest computer tomography (CT), supportive care, and clinical outcomes at discharge. This study was approved by the Moscow City Independent Ethics Committee (abbreviate 1, protocol number 74). Parental consent was sought during hospital admission and consent for the follow-up interview was sought via verbal confirmation during telephone interview.

180

197

181 Information about the current condition and persisting symptoms was collected by trained 182 medical students via telephone by interviewing the parent/carer of the child, using the 183 version 1 of the ISARIC COVID-19 Health and Wellbeing Follow Up Survey for Children, to 184 assess patients' physical and psychosocial wellbeing and behaviour, with local adaptations, 185 translated into Russian. The protocol was registered at The Open Science Framework ¹⁸. The 186 follow-up survey documented data on demographics, parental perception of changes in their 187 child's emotional and behavioural status, previous vaccination history, hospital stay and 188 readmissions, mortality (after the initial index event), history of newly developed symptoms 189 between discharge and the follow-up assessment, including symptom onset and duration, 190 and overall health condition compared to prior to the child's Covid-19 onset 191 (**Supplementary file**). To assess the prevalence of symptoms over time parents were asked 192 the following: (a) Within the last seven days, has your child had any of these symptoms, 193 which were NOT present prior to their Covid-19 illness? (If yes, please indicate below and 194 the duration of the symptom/s) and (b) Please report any symptoms that have been 195 bothering your child since discharge that are not present today. Please specify the time of 196 onset and duration of these symptoms.

198 Interviews were undertaken by a team of medical students with experience gained in 199 previous Covid-19 research ^{3,19} who underwent standardised training in telephone 200 assessment, REDCap data entry and data security. Assessments were conducted via 201 interviews with the parents/carers. Non-responders were contacted by telephone three times 202 before considering them lost to follow up.

203

204 Data management

REDCap electronic data capture tools (Vanderbilt University, Nashville, TN, USA) hosted at
 Sechenov University and Microsoft Excel (Microsoft Corp, Redmond, WA, USA) were used
 for data collection, storage and management ^{20,21}. The baseline characteristics, including
 demographics, symptoms on admission and comorbidities were extracted from EMRs and
 entered into REDCap.

210 Exposure and outcome variables

211 For the purposes of this study, we defined "persistent symptoms" as symptoms present at the 212 time of the follow-up interview and lasting for over 5 months. These were subcategorised 213 neurological, sensory, sleep, gastrointestinal, into respiratory, dermatological, 214 cardiovascular, fatigue and musculoskeletal (Table S1) informed by previously published 215 literature ^{22,23} and international expert group discussions.

216

217 Allergic diseases were defined as a presence of any of the following: asthma, allergic rhinitis, 218 eczema or food allergy. Health status before Covid-19 and at the time of the interview was 219 assessed using a 0 to 100 wellness scale ²⁴, where 0 was the worst possible health and 100 the 220 best possible health. Participants age categories were based on Eunice Kennedy Shriver 221 National Institute of Child Health and Human Development (NICHD) Pediatric Terminology 222 ²⁵. Severe disease was defined as having received non-invasive ventilation, invasive 223 ventilation or admission to the paediatric intensive care unit (PICU) during the hospital 224 admission.

225 Statistical analysis

Descriptive statistics were calculated for baseline characteristics. Continuous variables were
summarised as median (with interquartile range) and categorical variables as frequency
(percentage). The chi-squared test or Fisher's exact test was used for testing hypotheses on
differences in proportions between groups. The Wilcoxon rank-sum test was used for testing
the hypotheses on differences between groups.

We performed multivariable logistic regression to investigate associations of demographic
characteristics, co-morbidities (limited to those reported in ≥5% of participants), presence of
pneumonia during acute infection and severity of Covid-19 with persistent symptom
categories presence at the time of the follow-up interview. We included all participants for
whom the variables of interest were available in the final analysis, without imputing missing
data. The differing denominators used indicate missing data. Odds ratios were calculated
together with 95% confidence intervals (CIs).

239

Upset plots were used to present the coexistence of persistent symptom categories. Twosided p-values were reported for all statistical tests, a p-value below 0.05 was considered to
be statistically significant. Statistical analysis was performed using R version 3.5.1. Packages
used included dplyr, lubridate, ggplots2, plotrix and UpSetR.

244

245 Patient and public involvement

The survey was developed by the ISARIC Global Paediatric Covid-19 follow up working group and informed by a wide range of global stakeholders with expertise in infectious diseases, critical care, paediatrics, epidemiology, allergy-immunology, respiratory medicine, psychiatry, psychology and methodology and patient representatives. The survey was distributed to the members of the patient group and suggestions from parents/carers were implemented.

253 **RESULTS**

254 Study population

All 853 children hospitalised with suspected Covid-19 to the hospital between April 2, 2020

and August 26, 2020 were discharged alive (Figure 1). Of 836 patients with accurate

257 contact information, parents of 518 RT-PCR positive children agreed to be interviewed

(response rate 62%) and were included in the analysis.



259

Figure 1. Flow diagram of patients with COVID-19 admitted to Z.A. Bashlyaeva Children's Municipal

- 261 Clinical Hospital between April 2, 2020 and August 26, 2020.
- 262

263 The median age was 10.4 years (IQR, 3-15.2; range, 2 days–18 years), 272 (52.2%) were girls.

264 Median follow-up time since hospital admission was 268 days (IQR 233-284). Children had

a median of 8 (IQR, 4-9) years of formal school education and a median of 4 (IQR, 3-5)

family members were residing in the household (**Table 1**).

Characteristics	Total (n=518)
Sex, female	270 (52.1%)
Age at the time of hospital admission, years	10.4
(median, IQR)	(3-15.2)
Age (categorical), years	(22, 20/)
<2	105 (20.3%)
2-5	80 (15.4%)
6 - 11	113 (21.8%)
12 - 18	220 (42.5%)
Days from discharge to follow-up (median, IQR)	256 (223-271)
Length of hospital admission (days, median, IQK)	10 (7-14)
Number of years of formal school education (median, IQR)	8 (4-9)
Number of members in household (median, IQR)	4 (3-5)
Pneumonia during hospitalisation	192/515(37.3%)
Severe disease (non-invasive ventilation or invasive ventilation or PICU)	14/515(2.7%)
Comorbidities	
Neurological disorders	43/514 (8.4%)
Neurodisability	11/514 (2.1%)
Heart diseases	21/514 (4.1%)
Haematological conditions	10/514 (1.9%)
Tuberculosis	9/514 (1.8%)
Respiratory diseases (not including asthma)	16/514 (3.1%)
Allergic diseases [†]	121/514 (23.5%)
Food Allergy	67/514 (13%)
Allergic Rhinitis	46/514 (8.9%)
Eczema Asthma (doctor diagnosed)	45/514 (8.8%)
Other skin problems (not including eczema)	8/514 (1.6%)
Gastrointestinal problems	48/514 (9.3%)
Oncological conditions	3/514 (0.6%)
Immune system diseases	6/514 (1.2%)
Genetic conditions	6/514 (1.2%)
Diabetes*	3/514 (0.6%)
Other endocrine illness (not diabetes)	12/514 (2.2%)
Renal/Kidney problems	18/514 (2.5%)
Excessive weight and obesity	25/514 (4.0%)
Malnutrition	10/514 (1.0%)
Rheumatological conditions	4/514 (0.8%)
Depression	4/514 (0.8%)
Anvietz	4/514 (0.070)
	$\frac{5}{514}(1/6)$
111 v No comorbiditios	0(0/0)
One comorbidity	204/514(55.3%)
	141/514 (27.4%)
Two comorbidities or more	89/514 (17.3%)

268 Table 1. Demographic characteristics of patients admitted to the Z.A. Bashlyaeva Children's Municipal Clinical

Hospital. Data are n (%) or median (IQR) excluding missing values. *All cases of diabetes were type 1. †Allergic

270 diseases include asthma, allergic rhinitis, food allergy and eczema.

272 The most common pre-existing comorbidity in this cohort was food allergy (13%, 67/514), 273 followed by allergic rhinitis and asthma (9.7%, 50/514), gastrointestinal problems (9.3%, 274 48/514), eczema (8.8%, 45/514) and neurological problems (8.4%, 43/514). Parents of 55.3% 275 (284/514) children did not report any comorbidities. Fever (83.6%, 427/511), cough (55.7%, 276 284/510), rhinorrhea (54.3%, 278/512) and fatigue (38.9%, 197/506) were the most 277 common presenting symptoms at the time of the hospital admission (Table S2). 37.3%, 278 192/515 of patients had pneumonia during hospital stay, 2.7%, 14/515 had severe disease, 279 which required non-invasive ventilation/invasive ventilation or admission to PICU. 280 Treatments received during the hospital admission are presented in **Table S3**.

281

282 At the time of the follow-up interview, parents of 24.7% (128) children reported at least one

persistent symptom, with fatigue 10.6% (53/496), insomnia 5.19% (26/501), disturbed smell

284 4.7% (22/467) and headache 3.5% (17/486) being the most common. Detailed information

- on symptoms and duration is presented in **Table S4**.
- 286

The prevalence of most symptoms declined over time. Prevalence of reported fatigue fell from 15.8% (82/518) at the time of discharge to 11.1% (55/496) 6-7 months later, altered sense of smell fell from 8.7% (45/518) to 5.4% (27/496), altered sense of taste from 5.6% (29/518) to 3.8% (19/496) and breathing difficulties from 3.9% (20/518) to 1.4% (7/496), respectively. However, no change was observed in the prevalence of sleep disturbances or headache over time. Changes in the prevalence of the most common symptoms from the time of discharge over the next 6-7 months are shown in **Figure 2**.



295

Figure 2. Prevalence of the most common symptoms after hospital discharge. The prevalence was calculated
based on responses to the following questions: "Within the last seven days, has your child had any of these
symptoms, which were NOT present prior to their Covid-19 illness? (If yes, please indicate below and the duration
of the symptom/s) and "Please report any symptoms that have been bothering your child since discharge that are
not present today. Please specify the time of onset and duration of these symptoms."

301

With regard to persistent symptom categories (**Table S1**), fatigue was the most commonly reported in 10.6% (53/498) of patients at the time of assessment, followed by sleep disturbance 7.2% (36/501), sensory problems 6.2% (29/467), gastrointestinal 4.4% (22/499) and dermatological 3.6% (18/496) problems. A smaller number of patients experienced neurological 3% (14/465), respiratory 2.5% (12/489), cardiovascular 1.9% (9/470) and musculoskeletal 1.8% (9/489) problems long-term.

308

A total of 8.5% (44) participants reported persistent symptoms from more than one category at the time of the follow-up assessment. Most commonly co-occurring categories were fatigue and sleep problems in 1.9% (10) of children, and fatigue and sensory problems were present in 1.5% (8) of participants. 2.7% (14) of children had persistent symptoms from three or more different categories. Co-existence of persistent symptom categories at the time of the follow-up is presented in the upset plot (**Figure 3**).





317 Figure 3. Upset plot representing coexistence of the persistent symptom (present at the time of the follow-up

318 interview and lasting for over 5 months) categories at the follow-up assessment. The values represent the number

319 of individuals experiencing a persistent symptom category or combination of categories. Black lines link multiple

320 symptoms indicated by black dots.

321 The scores on the wellness scale for children with one or two or more persistent symptoms 322 significantly declined when compared to before Covid-19 onset from 90 (80-100) to 82.5 323 (70-93.8) and from 90 (80-95) to 70 (60-80) (p<0.001 for all comparisons), respectively. 324 Children who did not experience any persistent symptoms did not report any significant 325 changes in wellness when asked to compare to how they felt before their acute Covid-19 326 illness. We also assessed emotional difficulties, social relationships, and activity levels in children (Tables S4 - S5). Parents related the following changes to Covid-19 illness, and not 327 328 to the pandemic in general: less eating in 4.5% (23/512) of children, less sleeping in 3.5% (18/511) and more sleeping in 2% (10/511), reduced physical activity in 4.7% (24/512) and 329 330 child becoming less emotional in 4.3% (22/511). In contrast, parents attributed changes to 331 social activities to the pandemic in general rather than to the Covid-19 illness: 12% (58/485) of children were spending less time with their friends in person, while 13% (61/470) were 332 333 spending more time with friends remotely, with less than one percent of parents attributing 334 these changes to Covid-19 illness. 23% (110/478) of children were spending more time 335 watching television, playing video/computer games or using social media for educational 336 purposes, with 92.9% of parents associating these changes with the pandemic in general 337 rather than the Covid-19 illness.

338

339 In multivariable regression analysis, older age group was associated with persistent 340 symptoms. When compared with children under two years of ages, those ages 6-11 years had 341 an odds ratio of 2.74 (95% confidence interval 1.37 to 5.75) of persistent symptoms and those 342 12-18 years of age (OR 2.68, 95% CI 1.41 to 5.4) both vs. <2 years. Another predictor 343 associated with persistent symptoms was allergic diseases (OR 1.67, 95% CI 1.04 to 2.67). 344 Similar patterns were seen for children with co-existence of persistent symptoms from 2 or 345 more categories: 6-11 years of age (OR 2.49, 95% CI 1.02 to 6.72), 12-18 years of age (OR 346 3.18, 95% CI 1.43 to 8.11) both vs. <2 years.



349

348

Figure 4. Multivariable logistic regression model to identify pre-existing risk factors for post-COVID condition.

351 Odds ratios and 95% CIs for presence of (A) any category of persistent symptoms at the time of follow-up and (B)

352 two or more co-existing categories of persistent symptoms at the time of the follow-up. Abbreviation: CI, 353 confidence interval.

354 **DISCUSSION**

To our knowledge, this is the largest prospective paediatric cohort study with the longest 355 356 follow-up, assessing symptom prevalence and duration of long COVID in children and 357 adolescents with laboratory confirmed SARS-CoV-2 infection post hospital discharge. We found that a quarter of children and adolescents had persistent symptoms at the time of the 358 359 follow-up with fatigue, sleep disturbance and sensory problems being the most common. 360 Almost one in ten reported multi-system impacts with two or more categories of persistent symptoms at the time of the follow-up. Children in mid-childhood and adolescence (age 6-361 362 18) were at higher risk of persistent symptoms at the time of the follow-up. Although 363 prevalence of some symptoms declined over time, a substantial proportion experienced 364 problems up to 7-8 months after discharge.

365

There are very few studies assessing long COVID in children and adolescents; a previous smaller study from Italy found similar persisting symptoms during a shorter follow-up ²⁶. It is worth noting that although many parents reported nasal congestion/rhinorrhea in both studies, we found that nasal symptoms persisted long-term in a very small number of children. This highlights importance of symptom duration assessment as point prevalence of the symptom may not reflect its persistence and relevance to requirements for medical care and health/economics.

373

374 Although many children experienced symptoms, such as fatigue, disturbed smell and taste, 375 sleep and respiratory problems, hair loss and headaches at the time of the hospital discharge, 376 we witnessed a steady decline in the symptom prevalence over time. This was particularly 377 evident for fatigue and smell disturbance. Prevalence of some symptoms such as headache, 378 and sleep problems did not decline over time, which may be driven by psychological 379 mechanisms rather than pathophysiologic virus infection effects ²⁷. A limitation of these 380 findings is that symptom onset and duration was recalled at the single follow-up interview in 381 our study; this may be overcome with repeated follow-ups at appropriate intervals to limit 382 potential recall imprecision. In line with our results, previous research demonstrated 383 symptoms fading over time in adults ²² but data are still limited as most of the published cohort studies do not measure symptom duration, but rather assess their presence at a single 384 385 follow-up.

386

We found that almost one in ten children had multisystem impacts with two or more
categories of persistent symptoms present at the time of the follow-up. Similar numbers
were previously reported in the Russian adult population ³ and patients with clusters of

different symptoms were described in the UK ²⁸. Patients with multisystem involvement will
represent the primary target for the future research and intervention strategies development.

392

393 Age was significantly associated with persistent symptom presence at the time of the follow-394 up, with children above 6 years of age being at higher risk. To our knowledge, risk factors for 395 long Covid in children have not been investigated in previous studies, so we may draw 396 comparisons with the data from adult cohorts only. Previous data suggest that long Covid is 397 prevalent in adults ^{2,3,28-31} and that age is associated with a higher risk of long Covid ^{28,30}. An Australian follow-up study of 151 children aged 0-19 years (median 3 years) who had 398 399 predominantly mild acute covid-19 infection ¹⁵ found only 8% with on-going long-covid 400 symptoms. As acknowledged by the authors the low median age may be the main reason for 401 the low long-covid prevalence and our study substantiates this.

402

We found that allergic diseases in children were also associated with a higher risk of long Covid. This is in agreement with adult studies from Russia ³ and the UK ²⁸ reporting asthma to be associated with development of long Covid. Recent data suggested that COVID-19 consequences may be linked with the mast cell activation syndrome ³² and the Th-2 biased immunological response in children with allergic diseases may be responsible for an increased risk of long-term consequences from the infection. This highlights importance of further research of potential underlying immunological mechanisms of long Covid.

410

411 Apart from physical symptoms we assessed emotional and behavioural changes. Although 412 most parents reported no changes, one in twenty parents noticed changes in their children, 413 which they attributed to Covid-19 illness rather than the general situation during the pandemic. These included changes in eating, sleeping, emotional wellbeing and physical 414 415 activities. Over one in ten parents noted that their children were spending less time in face-416 to-face communication and more time interacting with their friends remotely and spending 417 time online for both educational and non-educational purposes. These changes were largely 418 attributed to the general situation during the pandemic rather than to the Covid-19 illness. 419 Of note, all surveyed children in our study had PCR-confirmed Covid-19 illness. It is 420 possible, however, that the predominance in remote vs in person interactions will have 421 longer term impacts in themselves. At present, to our knowledge, all publications on long 422 Covid are uncontrolled cohorts due to the difficulties of ascertaining data among controls 423 matched for age and sex but most importantly matched for the same experiences during the 424 pandemic aside from confirmed Covid-19 illness. There is a need to conduct studies with 425 reference groups of non-infected children to reliably assess mental health effects of the 426 pandemic and distinguish them from Covid-19 infection consequences.

427 A major strength of this study is that it was based on the ISARIC COVID-19 Health and 428 Wellbeing Follow Up Survey for Children which will assist with data harmonisation and 429 comparison with other international studies in the future. Another strength is the large 430 sample size of confirmed Covid-19 infected children, and this cohort has the longest follow-431 up assessment of hospitalised children to date. Stratification to determine if the symptoms 432 were persistent following Covid-19 and assessment of trends over time were other novel aspects of the study. At the same time, this cohort study has several limitations. First, the 433 434 study population only included patients within Moscow, although regional clustering is common to many cohort studies published during the Covid-19 pandemic. Second, it 435 436 included only hospitalised children, not representative of paediatric population. Third, we 437 did not have a control group of previously hospitalised children not experiencing Covid-19 infection. Fourth, some patients may have developed additional comorbidities or 438 439 complications since the hospital discharge, which were not appropriately captured and could 440 potentially affect the wellbeing and symptom prevalence and persistence. Fifth, the 441 parents/caregivers were interviewed in this study and not children themselves. There is also 442 a risk of recall bias in reporting symptoms which were non-existent at the time of the follow-443 up and potential selection bias with those with symptoms more likely to agree to survey.

444

Our findings have implications for further research. Longer follow up duration and repeated
assessments combined with controls and sampling for further studies into the
pathophysiology and immunology of post-Covid-19 illness sequelae are needed to inform
case definitions, and intervention trials aimed to improve long term outcomes.

449

450 Although many symptoms which were present at discharge diminished over time, even eight 451 months after hospital discharge many children experienced persistent symptoms, with 452 fatigue, sensory changes and sleep problems being the most common sequelae. One in ten 453 children experienced multi-system involvement at the time of the follow-up. Age and allergic 454 disease were the main risk factors for persistent symptoms. Future work should to be 455 multidisciplinary, prospective, with a control cohort, repeated sampling and with an ability 456 for children to report their health and wellbeing themselves, accompanied by biological 457 sample collection to establish causative mechanisms for a better understanding of Covid-19 458 sequelae and help with the phenotype/endotype categorisation. Investigation of 459 immunological aspects of the association between allergic diseases and long-covid 460 development may identify mechanisms and therapeutic targets for management to mitigate 461 potential adverse consequences.

- 462
- 463
- 464

We are very grateful to the Z.A. Bashlyaeva Children's Municipal Clinical Hospital clinical

465 Acknowledgments

467 staff and to the patients, parents, carers and families for their kindness and understanding 468 during these difficult times of COVID-19 pandemic. We would like to express our very great 469 appreciation to ISARIC Global COVID-19 follow-up working group for the survey 470 development. We would like to thank Mr Maksim Kholopov for providing technical support 471 in data collection and database administration. We are very thankful to Eat & Talk, Luch, 472 Black Market and Academia for providing us the workspace in time of need and their support 473 of Covid-19 research. Finally, we would like to extend our gratitude to the Global ISARIC 474 team, the ISARIC global adult and paediatric Covid-19 follow up working group, and ISARIC 475 Global support centre for their continuous support, expertise and for the development of the

- 476 outbreak ready standardised protocols for the data collection.
- 477

466

478 Funding statement

479 This study did not have external funding.

480 **REFERENCES**

481

482 1. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in
483 real time. *Lancet Infect Dis* 2020; **20**(5): 533-4.

484 2. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients
485 discharged from hospital: a cohort study. *Lancet* 2021; **397**(10270): 220-32.

Munblit D, Bobkova P, Spiridonova E, et al. Risk factors for long-term consequences
of COVID-19 in hospitalised adults in Moscow using the ISARIC Global follow-up protocol:
StopCOVID cohort study. *medRxiv* 2021: 2021.02.17.21251895.

- 489 4. Wise J. Long covid: WHO calls on countries to offer patients more rehabilitation. *BMJ* 490 2021; **372**: n405.
- 491 5. Meeting the challenge of long COVID. *Nat Med* 2020; **26**(12): 1803.

492 6. The L. Facing up to long COVID. *The Lancet* 2020; **396**(10266): 1861.

493 7. Ayoubkhani D. Prevalence of ongoing symptoms following coronavirus (COVID-19) 494 infection in the UK: April 2021. 2021. 495 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsandd 496 iseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk 497 /1april2021 (accessed 6-th of April 2021).

498 8. Oualha M, Bendavid M, Berteloot L, et al. Severe and fatal forms of COVID-19 in 499 children. *Arch Pediatr* 2020; **27**(5): 235-8.

500 9. Foster CE, Moulton EA, Munoz FM, et al. Coronavirus Disease 2019 in Children 501 Cared for at Texas Children's Hospital: Initial Clinical Characteristics and Outcomes. *J* 502 *Pediatric Infect Dis Soc* 2020; **9**(3): 373-7.

503 10. Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young 504 people admitted to hospital with covid-19 in United Kingdom: prospective multicentre 505 observational cohort study. *BMJ* 2020; **370**: m3249.

506 11. Gotzinger F, Santiago-Garcia B, Noguera-Julian A, et al. COVID-19 in children and 507 adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc* 508 *Health* 2020; **4**(9): 653-61.

509 12. Kim L, Whitaker M, O'Halloran A, et al. Hospitalization Rates and Characteristics of
510 Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET,
511 14 States, March 1-July 25, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69(32): 1081-8.

512 13. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J Med* 2020; **383**(4): 334-46.

514 14. Buonsenso D, Munblit D, De Rose C, et al. Preliminary Evidence on Long COVID in 515 children. *medRxiv* 2021: 2021.01.23.21250375.

516 15. Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19 517 outcomes in children with mild and asymptomatic disease. *Lancet Child Adolesc Health* 518 2021.

519 16. Michelen M, Manoharan L, Elkheir N, et al. Characterising long-term covid-19: a 520 rapid living systematic review. *medRxiv* 2020: 2020.12.08.20246025.

521 17. group IGPC-fuw. ISARIC Global COVID-19 paediatric follow-up. 2021.
 522 <u>https://isaric.org/research/covid-19-clinical-research-resources/paediatric-follow-up/</u>
 523 (accessed 24-th of April 2021).

18. Sigfrid L, Buonsenso D, DunnGalvin A, et al. Consequences of COVID-19 infection for child health and wellbeing: protocol for a prospective, observational, longitudinal study in children. 2021. <u>https://osf.io/d2wjn/</u> (accessed 21-st of April 2021).

527 19. Munblit D, Nekliudov NA, Bugaeva P, et al. StopCOVID cohort: An observational 528 study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city 529 for suspected COVID-19 infection. *Clin Infect Dis* 2020.

530 20. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. *J Biomed Inform* 2019; **95**: 103208.

532 21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research 533 electronic data capture (REDCap)--a metadata-driven methodology and workflow process 534 for providing translational research informatics support. *J Biomed Inform* 2009; **42**(2): 377-535 81.

536 22. Davis HE, Assaf GS, McCorkell L, et al. Characterizing Long COVID in an 537 International Cohort: 7 Months of Symptoms and Their Impact. *medRxiv* 2020: 538 2020.12.24.20248802.

539 23. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute 540 covid-19 in primary care. *BMJ* 2020; **370**: m3026.

541 24. Viner R, Gregorowski A, Wine C, et al. Outpatient rehabilitative treatment of chronic 542 fatigue syndrome (CFS/ME). *Arch Dis Child* 2004; **89**(7): 615-9.

543 25. Williams K, Thomson D, Seto I, et al. Standard 6: Age Groups for Pediatric Trials. 544 *Pediatrics* 2012; **129**(Supplement 3): S153-S60.

545 26. Buonsenso D, Munblit D, De Rose C, et al. Preliminary Evidence on Long Covid in 546 children. *Acta Paediatr* 2021.

547 27. Crawley SA, Caporino NE, Birmaher B, et al. Somatic complaints in anxious youth. 548 *Child Psychiatry Hum Dev* 2014; **45**(4): 398-407.

549 28. Sigfrid L, Drake TM, Pauley E, et al. Long Covid in adults discharged from UK 550 hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO 551 Clinical Characterisation Protocol. *medRxiv* 2021: 2021.03.18.21253888.

552 29. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and 553 psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using 554 electronic health records. *Lancet Psychiatry* 2021.

555 30. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat* 556 *Med* 2021.

557 31. Ayoubkhani D, Khunti K, Nafilyan V, et al. Post-covid syndrome in individuals 558 admitted to hospital with covid-19: retrospective cohort study. *BMJ* 2021; **372**: n693.

559 32. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-560 19 illness may be rooted in mast cell activation syndrome. *Int J Infect Dis* 2020; **100**: 327-32.